Welcome to our dedicated page for Adc Therapeutics Sa news (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on Adc Therapeutics Sa stock.
ADC Therapeutics SA (NYSE: ADCT) is a commercial-stage oncology company focused on antibody drug conjugates, and its news flow centers on clinical progress, regulatory developments, and corporate updates. The company’s primary product, ZYNLONTA (loncastuximab tesirine-lpyl), is a CD19-directed ADC approved under accelerated and conditional pathways for certain adults with relapsed or refractory diffuse large B-cell lymphoma after at least two prior systemic therapies.
News about ADCT commonly includes updates from its LOTIS clinical program, such as the Phase 3 LOTIS-5 trial of ZYNLONTA plus rituximab in second-line or later DLBCL and the Phase 1b LOTIS-7 trial evaluating ZYNLONTA in combination with bispecific antibodies and other agents in B-cell non-Hodgkin lymphoma. Company releases have highlighted response rates, safety findings, and enrollment milestones from LOTIS-7, as well as anticipated timelines for sharing full data and pursuing regulatory and compendia strategies.
Investors and followers of ADCT news will also find announcements on preliminary revenue and cash estimates, participation in healthcare conferences, and equity-related actions such as employee inducement grants and private placements. These items appear in both press releases and related Form 8-K filings, giving context on the company’s commercial performance and financing plans alongside its clinical pipeline.
This news page aggregates such disclosures so readers can track ADCT’s key events, from clinical trial readouts and investigator-initiated study updates in indolent lymphomas to progress on its early-stage PSMA-targeting ADC. For those monitoring ADCT stock, revisiting this page provides a consolidated view of the company’s evolving clinical, regulatory, and corporate narrative.
ADC Therapeutics (NYSE: ADCT) announced completion of enrollment in LOTIS-5, a Phase 3 confirmatory trial evaluating ZYNLONTA combined with rituximab for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). The study aims to confirm ZYNLONTA's 2021 accelerated FDA approval and potentially expand its label for 2L+ treatment with rituximab.
Part 1 of the trial showed promising results with an 80% overall response rate and 50% complete response rate. Part 2 randomizes patients 1:1 to receive ZYNLONTA with rituximab versus rituximab-gemcitabine-oxaliplatin. Topline results are expected by end of 2025, with potential FDA submission in Q1 2026 and approval targeted for late 2026.
ADC Therapeutics (NYSE: ADCT) announced positive initial data from the LOTIS-7 Phase 1b trial evaluating ZYNLONTA® in combination with glofitamab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The combination demonstrated a 94% best overall response rate and 72% complete response rate in evaluable patients.
The study included 29 B-NHL patients, with 18 evaluable 2L+ DLBCL patients receiving doses of 120 µg/kg or 150 µg/kg. At the 150µg/kg dose level, the combination achieved a 100% overall response rate and 78% complete response rate. Safety data showed no dose-limiting toxicities, with manageable Grade 3+ adverse events including neutropenia (24%), lymphopenia (7%), and hypokalemia (7%).
ADC Therapeutics announced updated data from two clinical trials evaluating ZYNLONTA®. In the first trial, ZYNLONTA combined with rituximab for relapsed/refractory follicular lymphoma showed a 97.4% overall response rate and 76.9% complete response rate, with 12-month progression-free survival of 94.6%. The study enrolled 39 patients with a median age of 68 years.
In the second trial, ZYNLONTA as monotherapy for relapsed/refractory marginal zone lymphoma demonstrated a 91% overall response rate and 70% complete response rate in 23 patients. The median duration of complete response was 11.5 months, with the longest follow-up at 27 months.
ADC Therapeutics (NYSE: ADCT) has announced a conference call and webcast scheduled for December 11, 2024, at 8:30 a.m. EST. The company will present preliminary data from the LOTIS-7 Phase 1b clinical trial, which evaluates ZYNLONTA® in combination with bispecific antibody glofitamab (COLUMVI™) for treating relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
The conference call will be accessible via toll-free dial-in for North America and Canada participants, and a webcast will be available on the company's investor relations website for 30 days following the presentation.
ADC Therapeutics announced the granting of options to purchase 34,900 common shares to three new employees as employment inducement. The grants, approved by the Compensation Committee under the Company's Inducement Plan, will vest over four years, with 25% vesting on the first anniversary and 1/48th monthly thereafter until full vesting on the fourth anniversary, contingent on continued employment. The grants were made under NYSE's Listed Company Manual Rule 303A.08 employment inducement exemption.
ADC Therapeutics reported Q3 2024 financial results with ZYNLONTA® net product revenues of $18.0 million, up from $14.3 million in Q3 2023. The company reported a net loss of $44.0 million ($0.42 per share) compared to $46.7 million in Q3 2023. Key operational updates include expected full enrollment in LOTIS-5 trial by year-end 2024, continued LOTIS-7 enrollment with interim data expected in December, and discontinuation of the ADCT-601 program. Cash position stands at $274.3 million, with runway extended into mid-2026 following a $97.4 million offering in May 2024.
ADC Therapeutics (NYSE: ADCT) announced two investigator-initiated study abstracts on ZYNLONTA accepted for presentation at the 66th ASH Annual Meeting. The Phase 2 study combining ZYNLONTA with rituximab in relapsed/refractory follicular lymphoma showed a 97.1% overall response rate among 35 patients, with an 80% best complete metabolic response rate. In a separate study for relapsed/refractory marginal zone lymphoma, ZYNLONTA as a single agent achieved an 85% overall response rate with 75% complete response rate in 20 evaluable patients. Both studies demonstrated safety profiles consistent with known ZYNLONTA data.
ADC Therapeutics (NYSE: ADCT), a commercial-stage leader in antibody drug conjugates, has announced its participation in two major investor conferences this November. The company will present at the Guggenheim Securities Healthcare Innovation Conference on November 11, 2024, at 11:00 a.m. ET, and the Jefferies London Healthcare Conference on November 19, 2024, at 11:00 a.m. GMT. Both presentations will feature CEO Ameet Mallik in fireside chat formats. Live webcasts will be available on the company's investor relations website, with replays accessible for approximately 30 days after each event.
ADC Therapeutics announced the grant of options to purchase 42,000 common shares to two new employees as employment inducement. The grants, approved by the Compensation Committee under the Company's Inducement Plan, will vest over four years, with 25% vesting on the first anniversary and 1/48th monthly thereafter until full vesting on the fourth anniversary, subject to continued employment.
ADC Therapeutics (NYSE: ADCT) announced it will host a conference call and live webcast on November 7, 2024, at 8:30 a.m. EST to discuss third quarter 2024 financial results and provide business updates. North American and Canadian participants can join via toll-free number 1-800-836-8184. The webcast will be available under 'Events and Presentations' on the company's investor relations website and archived for 30 days after the call.